Unum Therapeutics Announces Start of First Phase I Clinical Trial of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|
Unum Therapeutics announced that recruitment has begun in the first clinical trial of the ATTCK20 therapy. The Phase I study will examine the feasibility, safety and potential efficacy of infusing the ATTCK20 combination therapy in patients with B-cell malignancies and persistent disease following standard therapy. [Unum Therapeutics] Press Release
CPRIT Awards UTSW Faculty $22.5 Million for Recruitment and Research in Liver Cancer, Leukemia, and Immunotherapy
UT Southwestern Medical Center faculty was awarded seven grants totaling more than $22 million from the Cancer Prevention and Research Institute of Texas (CPRIT) for investigations into leukemia, liver cancer, and immunotherapy, as well as to recruit new faculty. [UT Southwestern Medical Center] Press Release
Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Actinium Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. [Actinium Pharmaceuticals, Inc.] Press Release
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.